Abstract
According to CHOICE-01, a phase III trial in China, the PD-1 inhibitor toripalimab plus chemotherapy improves progression-free survival in patients with untreated non–small cell lung cancer lacking actionable mutations. The findings boost combination chemo–immunotherapy, rather than chemotherapy alone, as the new standard for this population.
©2022 American Association for Cancer Research.
2022
American Association for Cancer Research.
You do not currently have access to this content.